Table 5.
Antibody titers by timeline.
| Kit, manufacturer, target, and Ab measured | 1st week (1–6 days) before seroconversion | 2nd to 3rd weeks (7–13 days) acute rising | 3rd to 4th weeks (14–27 days) peak titer | 5th to 15th weeks (28–104 days) waning titer | ||||
|---|---|---|---|---|---|---|---|---|
|
PRNT ND50
KDCA, SARS-CoV-2, total |
7.71 ± 9.68 | 938.57 ± 1889.93 | 1705.73 ± 2126.20 | 597.05 ± 870.22 | ||||
| ┕ P < 0.001 ┙ | ┕ P < 0.001 ┙ | ┕ P < 0.001 ┙ | ||||||
|
cPass sVNT, GenScript, RBD, total |
13.57 ± 15.64% | 46.81 ± 32.54% | 83.08 ± 17.00% | 74.53 ± 22.87% | ||||
| ┕ P < 0.001 ┙ | ┕ P < 0.001 ┙ | ┕ P < 0.01 ┙ | ||||||
|
Elecsys Anti-SARS-CoV-2, Roche, NP, IgG/IgA |
2.17 ± 7.07 COI | 3.48 ± 5.07 COI | 15.62 ± 15.00 COI | 36.30 ± 33.57 COI | ||||
| ┕ P < 0.01 ┙ | ┕ P < 0.001 ┙ | ┕ P < 0.001 ┙ | ||||||
|
Elecsys Anti-SARS-CoV-2 S, Roche, RBD, total |
6.16 ± 19.88 U/mL | 97.18 ± 321.84 U/mL | 486.81 ± 745.27 U/mL | 373.05 ± 502.61 U/mL | ||||
| ┕ P < 0.001 ┙ | ┕ P < 0.001 ┙ | ┕ P = 0.9394 ┙ | ||||||
|
SARS-CoV-2 IgG II Quant, Abbott, RBD, IgG |
34.65 ± 57.75 AU/mL | 5337.75 ± 15426.61 AU/mL | 16806.08 ± 21912.72 AU/mL | 5959.90 ± 8336.19 AU/mL | ||||
| ┕ P < 0.001 ┙ | ┕ P < 0.001 ┙ | ┕ P < 0.001 ┙ | ||||||
Ab, antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ND50, 50% neutralizing dose; KDCA, Korea Disease Control and Prevention Agency; sVNT, surrogate virus neutralization test; RBD, receptor-binding domain; NP, nucleocapsid.
The bold values indicate those with statistical significance.